TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04003155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fezolinetant
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fezolinetant
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fezolinetant
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fezolinetant
Description: Oral Tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Oral Tablet
Study: NCT02046915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imnovid (pomalidomide)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endoxan (Cyclophosphamide)
Study: NCT00612846

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic sphincterotomy and subsequent laparoscopic cholecystectomy
Description: Endoscopic sphincterotomy and subsequent laparoscopic cholecystectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic bile duct exploration during cholecystectomy
Description: Laparoscopic bile duct exploration during cholecystectomy
Study: NCT04816994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single-dose of cannabis oil
Description: Single-dose of cannabis oil in order to treat acute radicular pain

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single-dose of cannabis oil
Description: Single-dose of cannabis oil in order to treat acute radicular pain

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Giving a sub-linguistic olive oil that is similar in appearance and taste to cannabis oil
Study: NCT03779451

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 17-OHPC
Description: received weekly 250 mg 17 alpha-hydroxyprogesterone-caproate (cidolut depot) intramuscular injections started at 26-28 week and up to 37-weeks' gestation or delivery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vaginal progesterone
Description: vaginal progesterone suppositories (Cyclogest vaginal suppository) in a dose of 400 mg daily starting at 26-28 weeks of gestation till 37 weeks of gestation or delivery
Study: NCT01217411

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cognitive Assessment
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gamma-Secretase Inhibitor RO4929097
Description: Given PO

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Radiosurgery
Description: Undergo SRS

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Undergo SRS

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Whole-Brain Radiotherapy
Description: Undergo WBRT
Study: NCT03260842

Intervention type: DIAGNOSTIC_TEST
Intervention: Bio-Specimen Collection
Description: Collection of bio-specimens and observation over time.

Intervention type: DIAGNOSTIC_TEST
Intervention: Bio-Specimen Collection
Description: Collection of bio-specimens and observation over time.
Study: NCT04315038

Intervention type: PROCEDURE
Intervention: spinal anesthesia
Description: Plan to enroll 200 health volunteers and 40 neurodegenerative diseases patients with received spinal anesthesia. Blood will be collected at time point of pre-anesthesia 10 minutes and CSF samples will be collected at time point during spinal anesthesia induction. Blood will be collected, drawn into EDTA-coated tube.
Study: NCT00620165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levetiracetam
Description: Subjects will receive levetiracetam titrated up over 6 weeks to a maximum dose of 3000 milligrams (mg) per day, and then continue at 1500 mg twice daily for an additional 6 weeks.
Study: NCT01217411

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole-Brain Radiotherapy
Description: Undergo WBRT
Study: NCT00620165

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subjects will receive identical placebo titrated up over 6 weeks to a maximum daily dose, and then continue twice daily for an additional 6 weeks.
Study: NCT03944876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: Botulinum toxin 25 Allergan units in 0.5 ml Sodium Chloride (NaCl) 0.9 % Braun. One injection in the headache side of the face, targeted at the sphenopalatine ganglion (SPG)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 0.5 ml Sodium Chloride (NaCl) 0.9% Braun. One injection in the headache side of the face, targeted at the sphenopalatine ganglion (SPG)
Study: NCT02630277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: Intravitreal Aflibercept Injection 2.0 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: Intravitreal Aflibercept Injection 2.0 mg
Study: NCT01780389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Open-label flexibly dosed milnacipran
Study: NCT00830427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00610355
Description: 100 mcg, QD, dry powder inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF - 00610355
Description: 600 mcg, QD, dry powder inhaler
Study: NCT02677051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulforaphane
Description: Sulforaphane (1-isothiocyanato-4R- (methylsulfinyl)butane) is an isothiocyanate derived from the action of the plant enzyme myrosinase on glucosinolates including glucoraphanin and comes from consumption of many cruciferous vegetables.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02302833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib S-malate
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT00830427

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: QD, dry powder inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF - 00610355
Description: 300 mcg, QD, dry powder inhaler
Study: NCT04087655

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Eight weeks of interval exercise training
Study: NCT04114084

Intervention type: PROCEDURE
Intervention: Bone Marrow Aspirate and Biopsy
Description: The aspirate sample obtained for research at the time a standard-of-care biopsy is taking place will be approximately 40cc. Bone marrow aspiration removes bone marrow fluid and cells through a needle placed into the bone. Usually this sample is taken from the back of the pelvic bone, but it may also be taken from the sternum or the front of the pelvic bone. A bone marrow biopsy removes bone with the marrow inside and is done prior to the aspirate. Each biopsy and aspirate procedure takes approximately 15 minutes total. Bone marrow aspirate may be collected in a separate tube for research or collected from the standard-of-care specimen with left-over aspirate not otherwise needed for clinical purposes, or from previous procedures.
Study: NCT03008005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol Cap 10 milligrams (MG)
Description: Dronabinol (10mg) is administered only once (approximately 120 min prior to MR scanning in Visit 3) by the oral route and is placed in an opaque capsule with dextrose filler.
Study: NCT02597257

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine HCl
Description: lidocaine continuous infusion
Study: NCT00921505

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Tablet ibuprofen 400 mg oral single dose (1 tablet)
Study: NCT02597257

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline continuous infusion
Study: NCT01354470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil
Description: 600 mg Modafinil capsule
Study: NCT04997551

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchcine
Description: In patients not taking lopinavir / ritonavir or any other CYP3A4 or P-glycoprotein inhibitor drugs:~* Day 1: 1 single dose of 1 mg orally, in a single dose.~* Days 2 to 6: 0.5 mg every 12 hours v.o.~* Days 7 to 14: 0.5 mg / 24 hours v.o. In patients taking drugs that inhibit the CYP3A4 system or the P-glycoprotein, these drugs will be attempted to be discontinued. The dose in these cases will be: o 0.5 mg every 72 hours v.o. while taking the drug that interacts.~or 0.5 mg every 24 hours v.o. when, after suspending the interacting drug, at least 5 half-lives of the suspended drug have elapsed, from the last intake of said drug (in the case of lopinavir / ritonavir this would be a total of 24-30 hours) until the 14th day.~In patients older than 80 years or patients with CKD-EPI estimated glomerular renal failure filtration rate between 30 and 50 ml / min / 1.73 m2), the colchicine / placebo dose will be:~o Days 1 to 14: 0.5 mg / day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Colchcine
Description: In patients not taking lopinavir / ritonavir or any other CYP3A4 or P-glycoprotein inhibitor drugs:~* Day 1: 1 single dose of 1 mg orally, in a single dose.~* Days 2 to 6: 0.5 mg every 12 hours v.o.~* Days 7 to 14: 0.5 mg / 24 hours v.o. In patients taking drugs that inhibit the CYP3A4 system or the P-glycoprotein, these drugs will be attempted to be discontinued. The dose in these cases will be: o 0.5 mg every 72 hours v.o. while taking the drug that interacts.~or 0.5 mg every 24 hours v.o. when, after suspending the interacting drug, at least 5 half-lives of the suspended drug have elapsed, from the last intake of said drug (in the case of lopinavir / ritonavir this would be a total of 24-30 hours) until the 14th day.~In patients older than 80 years or patients with CKD-EPI estimated glomerular renal failure filtration rate between 30 and 50 ml / min / 1.73 m2), the colchicine / placebo dose will be:~o Days 1 to 14: 0.5 mg / day
Study: NCT02958176

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HRV Biofeedback
Description: At-home heart rate variability biofeedback using Elite HRV app and Polar H7 chest strap

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HRV Biofeedback
Description: At-home heart rate variability biofeedback using Elite HRV app and Polar H7 chest strap

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Autogenic Training
Description: Autogenic training recording provided on a CD
Study: NCT00688844

Intervention type: DRUG
Intervention: KuvanTM Therapy
Description: BH4 treatment was prescribed by each participant's medical provider, not an intervention that was assigned as part of the current study.
Study: NCT04114084

Intervention type: PROCEDURE
Intervention: Bone Marrow Aspirate and Biopsy
Description: The aspirate sample obtained for research at the time a standard-of-care biopsy is taking place will be approximately 40cc. Bone marrow aspiration removes bone marrow fluid and cells through a needle placed into the bone. Usually this sample is taken from the back of the pelvic bone, but it may also be taken from the sternum or the front of the pelvic bone. A bone marrow biopsy removes bone with the marrow inside and is done prior to the aspirate. Each biopsy and aspirate procedure takes approximately 15 minutes total. Bone marrow aspirate may be collected in a separate tube for research or collected from the standard-of-care specimen with left-over aspirate not otherwise needed for clinical purposes, or from previous procedures.

Intervention type: PROCEDURE
Intervention: Bone Marrow Aspirate and Biopsy
Description: The aspirate sample obtained for research at the time a standard-of-care biopsy is taking place will be approximately 40cc. Bone marrow aspiration removes bone marrow fluid and cells through a needle placed into the bone. Usually this sample is taken from the back of the pelvic bone, but it may also be taken from the sternum or the front of the pelvic bone. A bone marrow biopsy removes bone with the marrow inside and is done prior to the aspirate. Each biopsy and aspirate procedure takes approximately 15 minutes total. Bone marrow aspirate may be collected in a separate tube for research or collected from the standard-of-care specimen with left-over aspirate not otherwise needed for clinical purposes, or from previous procedures.
Study: NCT01196598

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercises
Description: Three individual initial sessions for learn about pelvic floor muscle localization and function; receive lifestyle advice and practice the exercises correctly.~The control group receive only lifestyle advice.~Followed by three months of home training with appointments each two weeks with physiotherapist.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercises
Description: Three individual initial sessions for learn about pelvic floor muscle localization and function; receive lifestyle advice and practice the exercises correctly.~The control group receive only lifestyle advice.~Followed by three months of home training with appointments each two weeks with physiotherapist.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercises
Description: Three individual initial sessions for learn about pelvic floor muscle localization and function; receive lifestyle advice and practice the exercises correctly.~The control group receive only lifestyle advice.~Followed by three months of home training with appointments each two weeks with physiotherapist.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercises
Description: Three individual initial sessions for learn about pelvic floor muscle localization and function; receive lifestyle advice and practice the exercises correctly.~The control group receive only lifestyle advice.~Followed by three months of home training with appointments each two weeks with physiotherapist.
Study: NCT03008616

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AMAG-423 (digoxin immune fab)
Description: AMAG-423 (digoxin immune fab) 3.2 mg/kg, 30 minute IV infusion, every 6 hours x 4 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline, 30 minute IV infusion, every 6 hours x 4 days
Study: NCT01721551

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Training will include a 45-60 min aerobic training on a rehabilitation cycle ergometer (Monark Rehab Trainer 881E) in the supine position during dialysis session. The intensity will progress from 30-40% of the maximum exercise power to 60-70%.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Treatment
Description: The CON group received no intervention but the usual treatment
Study: NCT03039816

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasaleze
Description: Nasaleze cellulose powder

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lactose powder in the same plastic container as Nasaleze and with the same taste
Study: NCT03431636

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immersion
Description: cold water immersion

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ice pack
Description: ice packs through the body

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: rest
Description: seated rest
Study: NCT00259194

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moving
Description: The patients are allowed to lift their head, arms and legs during the 2 hours.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Moving
Description: The patients are told not to move, to keep their legs and upper arms down and not to lift the head from the pillow in these 2 hours.
Study: NCT00913276

Intervention type: DRUG
Group type: OTHER
Intervention: Propofol

Intervention type: DRUG
Group type: OTHER
Intervention: Sevoflurane
Study: NCT02667769

Intervention type: OTHER
Group type: OTHER
Intervention: Fasting day
Description: A day of fasting started at 18.00 clock with a blood glucose test and is only started when on the same day no significant hypoglycemia (blood glucose \<55 mg / dl) occurred, and when at 18.00 clock the blood sugar in the defined target range (70-180 mg / dl) is. Carried out during the fasting day standardized blood samples for measurement of plasma glucose with an appropriate laboratory method at 18.00, 20:00, 22:00, 12:00, 2:00, 4:00, 6:45, 9:00, 12:00, 14:00 and again at 18.00 clock. Because the determination of plasma glucose in the laboratory will take some time, is always for guidance and also measured with a fast measurement method, in order to treat at high levels of blood sugar with additional insulin correction, and to treat hypoglycaemia low blood sugar or to prevent hypoglycaemia.

Intervention type: OTHER
Group type: OTHER
Intervention: Fasting day
Description: A day of fasting started at 18.00 clock with a blood glucose test and is only started when on the same day no significant hypoglycemia (blood glucose \<55 mg / dl) occurred, and when at 18.00 clock the blood sugar in the defined target range (70-180 mg / dl) is. Carried out during the fasting day standardized blood samples for measurement of plasma glucose with an appropriate laboratory method at 18.00, 20:00, 22:00, 12:00, 2:00, 4:00, 6:45, 9:00, 12:00, 14:00 and again at 18.00 clock. Because the determination of plasma glucose in the laboratory will take some time, is always for guidance and also measured with a fast measurement method, in order to treat at high levels of blood sugar with additional insulin correction, and to treat hypoglycaemia low blood sugar or to prevent hypoglycaemia.
Study: NCT04156737

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TECNIS Symfony plus IOL Model ZHR00V
Description: IOL replaces the natural lens removed during cataract surgery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Trifocal Intraocular lens
Description: IOL replaces the natural lens removed during cataract surgery
Study: NCT01886222

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Long-term mild hypothermia
Description: Hypothermia will be induced within 6 hours of injury and maintained at 34-35℃ for 5 days.Then the patients will be passively rewarmed to a temperature of 36 to 37˚C at a rate no greater than 0.5˚C/4 hours.

Intervention type: OTHER
Group type: OTHER
Intervention: Normothermia
Description: Patients assigned to the normothermia group will be kept at 36-37℃.
Study: NCT00283842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DVS SR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DVS SR
Study: NCT02049671

Intervention type: DRUG
Intervention: Growth Hormone Therapy
Study: NCT00283842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DVS SR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DVS SR

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01949532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib was administered by IV injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib was administered by IV injection.
Study: NCT03745313

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Edwards PASCAL Transcatheter Valve Repair System
Description: Repair of the tricuspid valve through a transcatheter approach
Study: NCT04392934

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: a conservative physiotherapy protocol
Description: 5 minutes of ultrasound (Business Line US 50, Medical Italia, Italy) at a frequency of 1 MHz and intensity of 1.5 watts/cm², 20 minutes of conventional TENS (BTL-5000, UK ) applied to the patients. Then Codman's exercises, shoulder wheel activity, isometric exercises, range of motion exercises, capsular stretching, scapular stabilization exercises, and muscle strengthening exercises were done by patients. After the treatment, cold pack was applied to the shoulder for 10 minutes. The modalities in the treatment program were applied for a total of 20 sessions 5 days per week.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: a conservative physiotherapy protocol
Description: 5 minutes of ultrasound (Business Line US 50, Medical Italia, Italy) at a frequency of 1 MHz and intensity of 1.5 watts/cm², 20 minutes of conventional TENS (BTL-5000, UK ) applied to the patients. Then Codman's exercises, shoulder wheel activity, isometric exercises, range of motion exercises, capsular stretching, scapular stabilization exercises, and muscle strengthening exercises were done by patients. After the treatment, cold pack was applied to the shoulder for 10 minutes. The modalities in the treatment program were applied for a total of 20 sessions 5 days per week.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: a conservative physiotherapy protocol
Description: 5 minutes of ultrasound (Business Line US 50, Medical Italia, Italy) at a frequency of 1 MHz and intensity of 1.5 watts/cm², 20 minutes of conventional TENS (BTL-5000, UK ) applied to the patients. Then Codman's exercises, shoulder wheel activity, isometric exercises, range of motion exercises, capsular stretching, scapular stabilization exercises, and muscle strengthening exercises were done by patients. After the treatment, cold pack was applied to the shoulder for 10 minutes. The modalities in the treatment program were applied for a total of 20 sessions 5 days per week.
Study: NCT04250402

Intervention type: PROCEDURE
Intervention: Resection
Description: Radical resection.

Intervention type: PROCEDURE
Intervention: Resection
Description: Radical resection.

Intervention type: PROCEDURE
Intervention: Resection
Description: Radical resection.

Intervention type: PROCEDURE
Intervention: Resection
Description: Radical resection.
Study: NCT03142958

Intervention type: DEVICE
Intervention: Integra Cadence Total Ankle System
Description: Primary or revision on total ankle replacement
Study: NCT01530516

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Brackets plus Forsus springs
Description: Full brackets and after completion of level and alignment insertion of Class II correctors (Forsus spring devices).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xbow plus full brackets
Description: Xbow appliance to be inserted first. After anteroposterior changes have been completed full brackets will be bonded and occlusion fine tuned